Ionis Pharmaceuticals, Inc.
(NASDAQ : ISIS)

( )
ISIS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.45%98.560.0%$1438.14m
BIIBBiogen, Inc. -0.36%242.511.7%$630.38m
AMGNAmgen, Inc. -0.79%220.461.3%$568.17m
GILDGilead Sciences, Inc. 0.60%60.251.0%$535.76m
VRTXVertex Pharmaceuticals, Inc. -0.63%216.501.9%$470.81m
REGNRegeneron Pharmaceuticals, Inc. -3.34%506.102.7%$447.76m
BNTXBioNTech SE -4.35%101.870.0%$424.45m
ILMNIllumina, Inc. 1.25%305.633.5%$377.98m
NVAXNovavax, Inc. 1.44%95.3392.9%$339.05m
EXASEXACT Sciences Corp. -2.72%117.2619.6%$289.27m
MGENMiragen Therapeutics, Inc. -4.62%16.500.7%$248.55m
SRRKScholar Rock Holding Corp. 3.14%42.700.0%$242.63m
APVOAptevo Therapeutics, Inc. -3.58%43.9218.3%$210.20m
SGENSeagen Inc. -2.05%164.635.8%$167.34m
ALXNAlexion Pharmaceuticals, Inc. 0.41%123.112.0%$161.56m

Company Profile

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.